Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : G1 therapeutics, inc. save search
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
Published: 2023-01-09 (Crawled : 12:00) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 1.73%
H: 4.55%
C: 0.76%
trials trilaciclib therapeutics phase 2
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023
Published: 2023-01-04 (Crawled : 12:00) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: -3.14%
H: 4.32%
C: -1.8%
free expected therapeutics bladder update cancer phase 2
G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment
Published: 2021-12-01 (Crawled : 12:30) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 6.41%
H: 0.0%
C: 0.0%
phase 2 trilaciclib trial therapeutics
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC)
Published: 2021-11-29 (Crawled : 13:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
phase 2 trilaciclib antibody drug trial therapeutics
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
trodelvy phase 2 trilaciclib antibody drug trial therapeutics
Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: 0.0%
phase 2 therapy cancer breast cancer trial trilaciclib t-cell
G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer
Published: 2021-06-14 (Crawled : 12:00) - biospace.com/
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 0.14%
H: 5.13%
C: 5.08%
phase 2 cancer trilaciclib bladder
G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)
Published: 2021-05-10 (Crawled : 11:00) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: -3.71%
phase 2 lung cancer cancer trilaciclib
G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium
Published: 2020-12-09 (Crawled : 22:01) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 4.26%
H: 3.68%
C: -1.53%
breast cancer cancer therapy phase 2 trilaciclib symposium
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.